Kymera Therapeutics KYMR Other Nonoperating Income
Other Nonoperating Income at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's other nonoperating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's other nonoperating income?
- Kymera Therapeutics (KYMR) reported other nonoperating income of $14.98M in Q1 2026.
- How has Kymera Therapeutics's other nonoperating income changed year-over-year?
- Kymera Therapeutics's other nonoperating income increased by 68.0% year-over-year, from $8.92M to $14.98M.
- What is the long-term trend for Kymera Therapeutics's other nonoperating income?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other nonoperating income has grown at a 198.2% compound annual growth rate (CAGR), from $486K to $38.42M.
- What does other nonoperating income mean?
- This metric represents income generated from activities outside of the company's core business operations, such as interest income, gains on investments, or foreign currency exchange gains. It provides insight into the financial returns generated by the company's treasury management and non-core assets. Investors monitor this to understand how peripheral financial activities contribute to the overall bottom line independent of operational performance.